COO

Business Context and Reporting Period

Company: The Cooper Companies, Inc. (COO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Second quarter and six months ended April 30, 2025
Business Overview: The Company operates through two primary segments: CooperVision (contact lenses) and CooperSurgical (fertility and women's health care products). The Company is a large accelerated filer with 199.5 million shares of common stock outstanding as of May 26, 2025.

Key Financial Metrics

Note: Debt and Cash figures represent balances as of April 30, 2025.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 6.3% in Q2 2025 and 5.0% for the six-month period compared to the prior year. CooperVision sales grew 5% (Q2) and 5% (6mo), while CooperSurgical sales grew 8% (Q2) and 6% (6mo).
• Profitability: Operating income increased 14% in Q2 and 17% for the six months. Gross margin expanded to 68% for the six months ended April 30, 2025, driven by efficiency gains and favorable product mix.
• Net Income: Q2 net income decreased slightly to $87.7 million from $88.9 million in Q2 2024, despite higher operating income, due to a higher effective tax rate (39.3% vs. 31.6%) and increased "Other expense, net."
• Other Expense: "Other expense, net" rose significantly to $16.1 million in Q2 2025 from $2.8 million in Q2 2024, primarily due to a $15.7 million loss on the disposal of a minority interest investment.
• Acquisitions: Growth in CooperSurgical was bolstered by the August 2024 acquisition of obp Surgical and a fertility company acquired in June 2024.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Commentary

Management remains optimistic about long-term prospects in contact lens and general healthcare markets. CooperVision is focusing on market penetration with single-use silicone hydrogel products and myopia management solutions (MiSight). CooperSurgical is expanding its fertility and women's health portfolio. The Company expects to meet anticipated cash needs for at least 12 months through operating cash flows and available credit facilities.

Risks and Contingencies

• Material Weakness in Internal Controls: The Company disclosed a material weakness in IT general controls for U.S. operations within the CooperSurgical segment related to ERP implementation, change management, and segregation of duties. Management is implementing remediation steps, but disclosure controls and procedures were deemed not effective as of April 30, 2025.
• Foreign Exchange: Unfavorable foreign exchange fluctuations offset approximately $7.7 million of sales growth in Q2 and $22.4 million for the six months.
• Legal Proceedings: The Company is involved in various lawsuits and claims but does not believe the ultimate resolution will have a material adverse effect.
• Share Repurchases: The Company repurchased 0.5 million shares for $40.6 million in the quarter. $215.8 million remains authorized under the current program.

Investor Verification Checklist

• Internal Control Remediation: Verify the progress and timeline for remediation of the material weakness in IT general controls within the CooperSurgical segment.
• Tax Rate Volatility: Monitor the effective tax rate, which increased to 39.3% in Q2 2025 due to valuation allowance changes and reduced share-based compensation tax benefits.
• Acquisition Integration: Assess the financial contribution and integration status of the obp Surgical and fertility company acquisitions on CooperSurgical margins.
• Debt Covenants: Confirm continued compliance with the 2024 Credit Agreement covenants (Total Leverage Ratio and Interest Coverage Ratio).
• Foreign Exchange Exposure: Evaluate the impact of currency fluctuations on future earnings, given the significant international operations.